Opko health CEO Phillip Frost buys $184,650 in stock

Phillip Frost, the CEO and Chairman of OPKO Health, Inc. (NASDAQ:OPK), has made a significant acquisition of the company's stock. According to a recent SEC filing, Frost purchased 125,000 shares of OPKO Health at a weighted average price of approximately $1.4772 per share, totaling an investment of $184,650. The purchase comes as InvestingPro data shows the stock trading near $1.46, with a current market capitalization of $980 million. The company's shares have gained about 9% over the past year, despite recent volatility. The shares were acquired on April 8, 2025, through Frost Gamma Investments Trust, where Frost serves as a trustee. Following this transaction, Frost holds 213,876,448 shares indirectly and 3,568,951 shares directly. The purchase reflects Frost's ongoing involvement and investment in the company, where he is a key executive and a major shareholder. According to InvestingPro, the company maintains strong liquidity with a current ratio of 3.43, though it faces near-term challenges with negative EBITDA. Get access to 10+ additional exclusive ProTips and comprehensive analysis through InvestingPro's detailed research reports, available for 1,400+ US stocks.

In other recent news, Opko Health reported its fourth-quarter 2024 earnings, exceeding expectations with an earnings per share (EPS) of $0.01 against a projected loss of $0.08. However, the company fell short on revenue, reporting $103.1 million compared to the anticipated $156.35 million. Opko Health's strategic restructuring efforts, including workforce reductions at BioReference Health, are expected to enhance profitability by 2025. In a significant transaction, Labcorp agreed to acquire Opko's laboratory testing businesses specializing in oncology, with the deal valued at $192.5 million plus an additional earn-out of up to $32.5 million. Additionally, Opko Health expanded its stock repurchase program, doubling the capacity to $200 million, reflecting confidence in its business strategy. H.C. Wainwright maintained its Buy rating for Opko Health, with a price target of $3.00, following these developments. Furthermore, Opko Health entered a collaboration with Entera Bio (NASDAQ:ENTX) to develop an oral treatment for obesity, sharing development costs and ownership interests. The company plans to submit an Investigational New Drug (IND) application to the FDA later this year for its modified OXM agonist peptide.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.